The Feldan Shuttle:
Breaking the Endosomal Barrier to Reach Untapped Therapeutic Targets
The Feldan Shuttle: Optimized for Functional, Safe, and Broad Delivery

Overcomes endosomal entrapment — a major obstacle to effective intracellular drug delivery

Enables local delivery of functional antisense oligonucleotides (ASOs) and other therapeutic cargos

Achieves rapid delivery into a wide range of cells and tissues, including the skin and lungs — two organs known for their challenging natural barriers that limit traditional delivery methods

With a robust safety profile demonstrated in preclinical studies, the Feldan Shuttle led to the advancement of our lead candidate, FLD-103, into clinical trials

Unlocking the Full Potential of Antisense Oligonucleotides with the Feldan Shuttle
The Power of Local Administration
Local administration offers key advantages that improve therapeutic outcomes:
Increases
Treatment Efficacy
Limits
Systemic Exposure
Improves
Safety Profile

Proof-of-Concept Publications
The Feldan Shuttle has been the subject of publications in renowned journals, demonstrating its ability to efficiently deliver therapeutic cargos into cells, where they can engage their intracellular targets. This peer-reviewed work — some developed in collaboration with academic partners — reflects our scientific engagement and our platform’s broad potential.

Shuttle peptide delivers base editor RNPs to rhesus monkey airway epithelial cells in vivo.
Katarina Kulhankova, Soumba Traore, Xue Cheng, Hadrien Benk-Fortin, Stéphanie Hallée, Mario Harvey, Joannie Roberge, Frédéric Couture, Sajeev Kohli, Thomas J. Gross, David K. Meyerholz, Garrett R. Rettig, Bernice Thommandru, Gavin Kurgan, Christine Wohlford-Lenane, Dennis J. Hartigan-O’Connor, Bradley P. Yates, Gregory A. Newby, David R. Liu, Alice F. Tarantal, David Guay & Paul B. McCray Jr., Nat Commun 14, 8051 (2023). doi: 10.1038/s41467-023-43904-w. PMID: 38052872

Engineered amphiphilic peptides enable delivery of proteins and CRISPR-associated nucleases to airway epithelia.
Krishnamurthy S, Wohlford-Lenane C, Kandimalla S, Sartre G, Meyerholz DK, Théberge V, Hallée S, Duperré AM, Del'Guidice T, Lepetit-Stoffaes JP, Barbeau X, Guay D, McCray PB Jr., Nat Commun. 2019 Oct 28;10(1):4906. doi: 10.1038/s41467-019-12922-y. PMID: 31659165

Membrane permeabilizing amphiphilic peptide delivers recombinant transcription factor and CRISPR-Cas9/Cpf1 ribonucleoproteins in hard-to-modify cells.
Del'Guidice T, Lepetit-Stoffaes JP, Bordeleau LJ, Roberge J, Théberge V, Lauvaux C, Barbeau X, Trottier J, Dave V, Roy DC, Gaillet B, Garnier A, Guay D. PLoS One. 2018 Apr 4;13(4):e0195558. doi: 10.1371/journal.pone.0195558. eCollection 2018. PMID:29617431